SIGN UP
LOG IN
I
IFRX
Inflarx
1.77
-0.07-4.05%Opening12:28 05/02 EDT
OPEN/PREV CLOSE1.840/1.850
TODAY RANGE1.739-1.870
VOL239.90K
MARKET CAP119.16M
52 WEEK RANGE0.8238-2.815
AVG VOL (3M)418.88K
% TURNOVER0.36%
TURNOVER--
P/E (TTM)-2.1819
% RANGE7.08%
EPS(TTM)-0.8135
P/E(FORWARD)-2.1957
P/B1.649
BVPS1.077
DIVIDEND--
P/S612.07
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP111.49M
SHARES OUTSTANDING67.13M
NEXT EARNINGS--
FREE FLOAT62.81M
LOT SIZE1
EX-DIV DATE--
News
Press Releases
Financial Reports
Profile
Barchart·2d ago
InflaRx to Report First Quarter 2025 Results on May 7, 2025
Dow Jones·3d ago
InflaRx Initiated at Overweight by Cantor Fitzgerald
TipRanks·04/24 21:28
InflaRx Approves Key Resolutions at Annual Shareholder Meeting
TipRanks·04/03 11:57
InflaRx N.V. Announces 2025 Annual General Meeting Agenda
TipRanks·03/31 10:16
InflaRx’s Promising Drug Pipeline and Market Potential Drive Buy Rating
Benzinga·03/26 16:26
Carnival To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Wednesday
Dow Jones·03/26 13:48
InflaRx Price Target Raised to $10.00/Share From $7.00 by Guggenheim
Benzinga·03/26 13:38
Guggenheim Maintains Buy on InflaRx, Raises Price Target to $10
TipRanks·03/26 11:06
InflaRx price target raised to $10 from $7 at Guggenheim
TipRanks·03/21 20:25
LifeSci Capital Remains a Hold on InflaRx (IFRX)
Dow Jones·03/21 11:38
InflaRx Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Benzinga·03/21 11:28
HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.